Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 188 publications
Natriuretic Peptide and Transthyretin and Their Relationship With Clinical Outcomes: Results From ATTRIBUTE-CM, a Randomized Controlled Trial.
Journal: Journal of the American Heart Association
Published: August 31, 2026
124I-Evuzamitide Positron Emission Tomography/Computed Tomography for Diagnosing Cardiac Amyloidosis: The REVEAL Nonrandomized Clinical Trial.
Journal: JAMA
Published: August 30, 2026
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Effect of acoramidis on risk of death and heart problem-related hospitalizations in people with transthyretin amyloid cardiomyopathy: a plain language summary.
Journal: Future cardiology
Published: August 05, 2026
Effect of Acoramidis on Heart Failure-Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial.
Journal: JAMA cardiology
Published: July 29, 2026
Breaking the Anchor: Overcoming Diagnostic Bias in Overlapping Cardiac Pathologies.
Journal: Circulation
Published: June 22, 2026
Sex Differences in a Contemporary, Real-World Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis.
Journal: Cardiology and therapy
Published: May 27, 2026
Design and rationale of the Research with EVuzamitide to Evaluate for cardiac AmyLoidosis (REVEAL) positron emission tomography study: A study of 124I-evuzamitide to diagnose cardiac amyloidosis.
Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Published: May 21, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
Journal: Circulation. Heart failure
Published: May 09, 2026
Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.
Journal: Journal of cardiac failure
Published: May 08, 2026
Efficacy of Acoramidis in Transthyretin Amyloid Cardiomyopathy With and Without Atrial Fibrillation: Results From ATTRibute-CM.
Journal: Journal of cardiac failure
Published: May 08, 2026
Last Updated: 09/26/2026